Cited 0 times in
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2023-07-12T02:25:20Z | - |
dc.date.available | 2023-07-12T02:25:20Z | - |
dc.date.issued | 2023-02 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195303 | - |
dc.description.abstract | Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm advanced non-small cell lung cancer. This analysis identifies acquired resistance mechanisms to first-line osimertinib. Next-generation sequencing assesses circulating-tumor DNA from paired plasma samples (baseline and disease progression/treatment discontinuation) in patients with baseline EGFRm. No EGFR T790M-mediated acquired resistance are observed; most frequent resistance mechanisms are MET amplification (n = 17; 16%) and EGFR C797S mutations (n = 7; 6%). Future research investigating non-genetic acquired resistance mechanisms is warranted. © 2023. The Author(s). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Nature Pub. Group | - |
dc.relation.isPartOf | NATURE COMMUNICATIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / genetics | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / genetics | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Protein Kinase Inhibitors / pharmacology | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.title | Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Juliann Chmielecki | - |
dc.contributor.googleauthor | Jhanelle E Gray | - |
dc.contributor.googleauthor | Ying Cheng | - |
dc.contributor.googleauthor | Yuichiro Ohe | - |
dc.contributor.googleauthor | Fumio Imamura | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Meng-Chih Lin | - |
dc.contributor.googleauthor | Margarita Majem | - |
dc.contributor.googleauthor | Riyaz Shah | - |
dc.contributor.googleauthor | Yuri Rukazenkov | - |
dc.contributor.googleauthor | Alexander Todd | - |
dc.contributor.googleauthor | Aleksandra Markovets | - |
dc.contributor.googleauthor | J Carl Barrett | - |
dc.contributor.googleauthor | Ryan J Hartmaier | - |
dc.contributor.googleauthor | Suresh S Ramalingam | - |
dc.identifier.doi | 10.1038/s41467-023-35961-y | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02293 | - |
dc.identifier.eissn | 2041-1723 | - |
dc.identifier.pmid | 36849494 | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1070 | - |
dc.identifier.bibliographicCitation | NATURE COMMUNICATIONS, Vol.14(1) : 1070, 2023-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.